Publications - Curtana Pharmaceuticals

Links on this page will lead you to another website. These links are for informational purposes only; Curtana Pharmaceuticals assumes no responsibility for the content outside our website.

Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179

Li, Y., Lim, C., Dismuke, T. et al.

Nat Commun 16, 1091 (2025).
OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma

Desai, K., Wanggou, S., Luis, E. et al.

Nat Commun 16, 1092 (2025).
Fitness Screens Map State-Specific Glioblastoma Stem Cell Vulnerabilities

Graham MacLeod, Fatemeh Molaei, Shahan Haider, Maira P. Almeida, Sichun Lin, Michelle Kushida, Haresh Sureshkumar, Jasmine K. Bhatti, Jack Q. Lu, Daniel Schramek, Peter B. Dirks, Stephane Angers

Cancer Res 1 December 2024; 84 (23): 3967–3983.
Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration

Myers, B.L., Brayer, K.J., Paez-Beltran, L.E. et al.

Nat Commun 15, 10363 (2024).
Biological functions of the Olig gene family in brain cancer and therapeutic targeting

Szu JI, Tsigelny IF, Wojcinski A, Kesari S.

Front Neurosci. 2023 May 18;17:1129434.
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma

Zhenhua Xu, Najiba Murad, Daniel Malawsky, Ran Tao, Samuel Rivero-Hinojosa, Dörthe Holdhof, Ulrich Schüller, Peng Zhang, Christopher Lazarski, Brian R. Rood, Roger Packer, Timothy Gershon, Yanxin Pei;

Clin Cancer Res 1 October 2022; 28 (19): 4278–4291.
Novel Small Molecule Inhibitors Of The OLIG2 Transcription Factor: Promising New Therapeutics For Glioblastoma

Alton, G., & Kesari, S.

Future Oncology (London, England), 2016:12(8), 1001–4.
Multiple Spatially Related Pharmacophores Define Small Molecule Inhibitors of OLIG2 in Glioblastoma

Tsigelny, I. F., Mukthavaram, R., Kouznetsova, V. L., Chao, Y., Babic, I., Nurmemmedov, E., … Kesari, S. (2015).

Oncotarget, Oct 30(Online). doi:10.18632/oncotarget.5633
Antagonistic Modulation of Gliomagenesis by Pax6 And OLIG2 in PDGF-Induced Oligodendroglioma

Appolloni I, Calzolari F, Barilari M, Terrile M, Daga A, Malatesta P.

International Journal Of Cancer (Journal International du Cancer). 2012;131(7):E1078–87.
The Central Nervous System-Restricted Transcription Factor OLIG2 Opposes P53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma

Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta J a, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD.

Cancer cell. 2011;19(3):359–71.
Malignant Gliomas in Adults

Wen PY, Kesari S.

The New England journal of medicine. 2008;359(5):492–507.
OLIG2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma

Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta J a, Bachoo RM, Kane M, Louis DN, Depinho R a, Anderson DJ, Stiles CD, Rowitch DH.

Neuron. 2007;53(4):503–17.
The Oligodendroglial Lineage Marker OLIG2 is Universally Expressed in Diffuse Gliomas

Ligon KL, Alberta J a, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH.

Journal of neuropathology and experimental neurology. 2004;63(5):499–509.